Donor CMV Seropositivity Tied to Worse Survival in CMV‑Seronegative AML Patients Undergoing Unrelated HCT with Post‑Transplant Cyclophosphamide
Highlights
– In CMV‑seronegative adult AML patients undergoing unrelated donor HCT with post‑transplant cyclophosphamide (PTCy), receipt of a CMV‑seropositive donor was associated with inferior overall survival (multivariable HR 1.51; 95% CI 1.07–2.14).
– Restricted mean survival time (RMST) favored CMV‑seronegative donors by 2.95 months over the study follow‑up (P = .045); restricted mean time lost (RMTL) ratio was 1.34 (P = .037) for CMV‑seropositive donors.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.